Hims & Hers Expands into Multi-Billion Dollar Men’s Health Market

Telehealth provider Hims & Hers Health is making a bold strategic move to capture a significant share of the lucrative testosterone therapy market. The company announced a landmark partnership that could unlock substantial new revenue streams beyond its established hair loss and weight management treatments.

Strategic Pharmaceutical Partnership Announced

On September 10, Hims & Hers revealed an exclusive collaboration with Marius Pharmaceuticals that positions the company to enter a massive underserved market. Beginning in 2026, the platform will offer KYZATREX®, an FDA-approved oral testosterone medication that eliminates the need for injections. Clinical trial data demonstrates impressive efficacy, with testosterone levels restored in up to 96% of treated patients and free testosterone concentrations doubling.

The company isn’t waiting until 2026 to build its men’s health presence. Physicians on the platform can currently prescribe customized doses of Enclomiphene. For men experiencing sexual health concerns, the company offers personalized combination therapies incorporating both Enclomiphene and Tadalafil. This approach is particularly notable because Enclomiphene works by restoring the body’s natural testosterone production without compromising fertility.

Addressing a Vast Untapped Market

The market opportunity is substantial, with approximately 20 million American men affected by low testosterone levels. CEO Andrew Dudum explained the strategic rationale behind the expansion: “Historically, treatment for low testosterone has been stagnant, stigmatized, costly, and inaccessible for the majority of men.”

Should investors sell immediately? Or is it worth buying Hims & Hers?

Hims & Hers is applying its proven telehealth model to this challenge. The process begins with a simple at-home blood test that delivers results within days—dramatically faster than the traditional healthcare system’s multi-month waiting periods. Licensed physicians then develop individualized treatment plans supported by the company’s digital platform, which provides around-the-clock patient care.

Strong Growth Meets Market Skepticism

This expansion builds on impressive momentum. For the second quarter of 2025, the company reported revenue surged 73% to $544.8 million. With over 2.4 million active subscribers, Hims & Hers has demonstrated its ability to effectively scale personalized healthcare solutions.

Despite these strong fundamentals, investors have shown caution. After reaching peaks above $72 per share in February, the stock has retreated significantly. The testosterone initiative represents a potential catalyst for renewed momentum, though the full business impact won’t materialize until 2026. Until then, shareholders must rely on other growth drivers while awaiting the fruition of these ambitious expansion plans.